AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 Mg Or 30 Mg) In Patients With Moderate-to-severe Atopic Dermatitis
AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 Mg Or 30 Mg) In Patients With Moderate-to-severe Atopic Dermatitis
艾伯維公司宣佈了在Measure Up 1和Measure Up 2第3期研究中對Upadacitinib（15毫克或30毫克）在中重度特應性皮炎患者中進行的一項新的事後分析的結果
AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 Mg Or 30 Mg) In Patients With Moderate-to-severe Atopic Dermatitis
艾伯維公司宣佈了在Measure Up 1和Measure Up 2第3期研究中對Upadacitinib（15毫克或30毫克）在中重度特應性皮炎患者中進行的一項新的事後分析的結果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。